Literature DB >> 18650851

A strategy for genetic modification of the spike-encoding segment of human reovirus T3D for reovirus targeting.

D J M van den Wollenberg1, S K van den Hengel, I J C Dautzenberg, S J Cramer, O Kranenburg, R C Hoeben.   

Abstract

Human Orthoreovirus Type 3 Dearing is not pathogenic to humans and has been evaluated clinically as an oncolytic agent. Its transduction efficiency and the tumor cell selectivity may be enhanced by incorporating ligands for alternative receptors. However, the genetic modification of reoviruses has been difficult, and genetic targeting of reoviruses has not been reported so far. Here we describe a technique for generating genetically targeted reoviruses. The propagation of wild-type reoviruses on cells expressing a modified sigma 1-encoding segment embedded in a conventional RNA polymerase II transcript leads to substitution of the wild-type genome segment by the modified version. This technique was used for generating reoviruses that are genetically targeted to an artificial receptor expressed on U118MG cells. These cells lack the junction adhesion molecule-1 and therefore resist infection by wild-type reoviruses. The targeted reoviruses were engineered to carry the ligand for this receptor at the C terminus of the sigma 1 spike protein. This demonstrates that the C terminus of the sigma 1 protein is a suitable locale for the insertion of oligopeptide ligands and that targeting of reoviruses is feasible. The genetically targeted viruses can be propagated using the modified U118MG cells as helper cells. This technique may be applicable for the improvement of human reoviruses as oncolytic agents.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18650851     DOI: 10.1038/gt.2008.118

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  16 in total

1.  Reovirus variants with mutations in genome segments S1 and L2 exhibit enhanced virion infectivity and superior oncolysis.

Authors:  Maya Shmulevitz; Shashi A Gujar; Dae-Gyun Ahn; Adil Mohamed; Patrick W K Lee
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

2.  Replicating reoviruses with a transgene replacing the codons for the head domain of the viral spike.

Authors:  D J M van den Wollenberg; I J C Dautzenberg; W Ros; A D Lipińska; S K van den Hengel; R C Hoeben
Journal:  Gene Ther       Date:  2015-01-15       Impact factor: 5.250

3.  Generation of genetically stable recombinant rotaviruses containing novel genome rearrangements and heterologous sequences by reverse genetics.

Authors:  Aitor Navarro; Shane D Trask; John T Patton
Journal:  J Virol       Date:  2013-03-27       Impact factor: 5.103

4.  Engineering recombinant reoviruses with tandem repeats and a tetravirus 2A-like element for exogenous polypeptide expression.

Authors:  Aleksander A Demidenko; Joseph N Blattman; Negin N Blattman; Philip D Greenberg; Max L Nibert
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-29       Impact factor: 11.205

Review 5.  Changing faces in virology: the dutch shift from oncogenic to oncolytic viruses.

Authors:  Zineb Belcaid; Martine L M Lamfers; Victor W van Beusechem; Rob C Hoeben
Journal:  Hum Gene Ther       Date:  2014-09-17       Impact factor: 5.695

Review 6.  Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity.

Authors:  Jun Gong; Esha Sachdev; Alain C Mita; Monica M Mita
Journal:  World J Methodol       Date:  2016-03-26

7.  Generation of Genetically RGD σ1-Modified Oncolytic Reovirus That Enhances JAM-A-Independent Infection of Tumor Cells.

Authors:  Takahiro Kawagishi; Yuta Kanai; Ryotaro Nouda; Ichika Fukui; Jeffery A Nurdin; Yoshiharu Matsuura; Takeshi Kobayashi
Journal:  J Virol       Date:  2020-11-09       Impact factor: 5.103

8.  Gastrointestinal cancer-associated fibroblasts expressing Junctional Adhesion Molecule-A are amenable to infection by oncolytic reovirus.

Authors:  Lukas J A C Hawinkels; Vera Kemp; Tom J Harryvan; Matteo Golo; Nicole Dam; Mark J A Schoonderwoerd; Elham Aida Farshadi; Marten Hornsveld; Rob C Hoeben
Journal:  Cancer Gene Ther       Date:  2022-07-22       Impact factor: 5.854

9.  Isolation of reovirus T3D mutants capable of infecting human tumor cells independent of junction adhesion molecule-A.

Authors:  Diana J M van den Wollenberg; Iris J C Dautzenberg; Sanne K van den Hengel; Steve J Cramer; Raoul J de Groot; Rob C Hoeben
Journal:  PLoS One       Date:  2012-10-24       Impact factor: 3.240

10.  Development of measles virus-based shielded oncolytic vectors: suitability of other paramyxovirus glycoproteins.

Authors:  A W Hudacek; C K Navaratnarajah; R Cattaneo
Journal:  Cancer Gene Ther       Date:  2013-01-11       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.